RxDoctor Payments DataLook up a doctor →

Margaret Frey, DO

Neurology · Owosso, MINPI 1215134101

Payments from drug & device makers

$539,796in general payments, 2019–2025

Across 625 payments — averaging $863.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$484K
  • AbbVie$32K
  • Genentech USA, Inc.$12K
  • Grifols USA, LLC$6K
  • Genentech, Inc.$3K
  • Livanova USA, Inc.$1K
  • plus $2K from 35 others
$1,539in research payments, 2019–2025

Across 1 payment — averaging $1538.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$2K

What the payments were for

  • Consulting fees$40,91713%
  • Speaking & faculty fees$232,23472%
  • Travel & lodging$39,29312%
  • Food & beverage$8,6543%
  • Education$3100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$539,796 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$36,131
Medicare patients
180
Services billed
1,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EvrysdiRisdiplam44$1,164,666
Radicava OrsEdaravone38$593,506
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5060$568,406
SkyclarysOmaveloxolone12$387,212
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5044$259,210
NuplazidPimavanserin Tartrate14$70,812
BriviactBrivaracetam21$55,998
Emgality PenGalcanezumab-Gnlm76$53,229
UbrelvyUbrogepant26$30,940
QuliptaAtogepant24$25,520
Nurtec OdtRimegepant Sulfate16$24,696
XcopriCenobamate15$18,985
Tetrabenazine26$8,947
Lacosamide55$6,819
Riluzole13$5,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Evrysdi$11,879$1,164,66644 claims
BiogenSkyclarys$483,656$387,21212 claims
Acadia Pharmaceuticals IncNuplazid$62$70,81214 claims
AbbVieUbrelvy, Qulipta$32,351$56,46050 claims
UCB, Inc.Briviact$265$55,99821 claims
PfizerNurtec Odt, Dilantin$19$26,59927 claims
SK Life Science, Inc.Xcopri$103$18,98515 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$24$2,36827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 neurology providers in Michigan.

Other neurology in Owosso

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →